First to market and portfolio expansion
The strategy for Mylan in the UK is to identify patented products and endeavour to make them available as a generic on the day of patent expiry. Mylan has an outstanding record of success in introducing off-patent medicines, which is reflected by our extensive product range. We have been first to market with a number of significant off-patent molecules and also look to expand our product range through business development opportunities with other pharmaceutical companies.
(Last Updated: 01-06-2012)